AU2221299A - Lipooligosaccharide-based vaccine for prevention of (moraxella) ((branhamella)) (catarrhalis) infections in mammals - Google Patents

Lipooligosaccharide-based vaccine for prevention of (moraxella) ((branhamella)) (catarrhalis) infections in mammals Download PDF

Info

Publication number
AU2221299A
AU2221299A AU22212/99A AU2221299A AU2221299A AU 2221299 A AU2221299 A AU 2221299A AU 22212/99 A AU22212/99 A AU 22212/99A AU 2221299 A AU2221299 A AU 2221299A AU 2221299 A AU2221299 A AU 2221299A
Authority
AU
Australia
Prior art keywords
dlos
los
catarrhalis
hmp
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22212/99A
Other languages
English (en)
Inventor
Xin-Xing Gu
John B Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2221299A publication Critical patent/AU2221299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU22212/99A 1998-01-13 1999-01-12 Lipooligosaccharide-based vaccine for prevention of (moraxella) ((branhamella)) (catarrhalis) infections in mammals Abandoned AU2221299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7148398P 1998-01-13 1998-01-13
US60071483 1998-01-13
PCT/US1999/000590 WO1999036086A1 (en) 1998-01-13 1999-01-12 Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003200964A Division AU2003200964B2 (en) 1998-01-13 2003-02-21 Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) Catarrhalis Infections in Mammals

Publications (1)

Publication Number Publication Date
AU2221299A true AU2221299A (en) 1999-08-02

Family

ID=22101617

Family Applications (2)

Application Number Title Priority Date Filing Date
AU22212/99A Abandoned AU2221299A (en) 1998-01-13 1999-01-12 Lipooligosaccharide-based vaccine for prevention of (moraxella) ((branhamella)) (catarrhalis) infections in mammals
AU2003200964A Ceased AU2003200964B2 (en) 1998-01-13 2003-02-21 Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) Catarrhalis Infections in Mammals

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003200964A Ceased AU2003200964B2 (en) 1998-01-13 2003-02-21 Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) Catarrhalis Infections in Mammals

Country Status (9)

Country Link
EP (1) EP1047447A1 (ja)
JP (1) JP2002509115A (ja)
KR (1) KR20010034124A (ja)
CN (1) CN1288384A (ja)
AU (2) AU2221299A (ja)
BR (1) BR9906902A (ja)
CA (1) CA2315746A1 (ja)
IL (1) IL136903A0 (ja)
WO (1) WO1999036086A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126381A1 (en) 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
WO2002089839A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
WO2006085910A2 (en) * 2004-06-04 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Endotoxin-free moraxella catarrhalis
CN104592365B (zh) * 2013-11-01 2019-06-14 中国人民解放军军事医学科学院毒物药物研究所 梭曼抗原、梭曼疫苗及其用途
WO2019084632A1 (en) * 2017-11-06 2019-05-09 The Crown in right of the State of New South Wales acting through the Department of Primary Industries as an office of the Department of Industry Vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053851A1 (en) * 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria

Also Published As

Publication number Publication date
WO1999036086A1 (en) 1999-07-22
JP2002509115A (ja) 2002-03-26
BR9906902A (pt) 2000-10-17
AU2003200964A1 (en) 2003-06-12
CN1288384A (zh) 2001-03-21
AU2003200964B2 (en) 2004-11-11
CA2315746A1 (en) 1999-07-22
EP1047447A1 (en) 2000-11-02
KR20010034124A (ko) 2001-04-25
AU2003200964A8 (en) 2003-06-12
IL136903A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
US6531131B1 (en) Conjugate vaccine for Neisseria meningitidis
US6207157B1 (en) Conjugate vaccine for nontypeable Haemophilus influenzae
US9533032B2 (en) Protein matrix vaccines and related methods of making and administering such vaccines
AU669854B2 (en) Escherichia coli O-polysaccharide-protein conjugate vaccine
US6685949B1 (en) Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
CA2647455A1 (en) Processes for the conjugation of poly n-acetylated glucosamine to a carrier protein
WO1992004915A1 (en) Improved vaccine compositions
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
AU2003200964B2 (en) Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) Catarrhalis Infections in Mammals
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
Zou et al. Preparation of glycoconjugate vaccines
EP0471954A2 (en) Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
JP5967585B2 (ja) ワクチンとして使用される無毒化大腸菌易熱性エンテロトキシン（ｌｔ）との多糖結合
US20030068324A1 (en) Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
MXPA00006678A (en) Lipooligosaccharide-based vaccine for prevention of moraxella
Robbins et al. Synthesis and Characterization of
CA2446355A1 (en) Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
AU2002211782A1 (en) Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted